Eris Lifesciences [ERIS] vs Sun Pharmaceutical [SUNPHARMA] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Eris Lifesciences Ltd. wins in 6 metrics, Sun Pharmaceutical Industries Ltd. wins in 14 metrics, with 0 ties. Sun Pharmaceutical Industries Ltd. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Eris Lifesciences Ltd. | Sun Pharmaceutical Industries Ltd. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 44.25 | 36.73 | Sun Pharmaceutical Industries Ltd. |
| Price-to-Book Ratio | 6.15 | 5.15 | Sun Pharmaceutical Industries Ltd. |
| Debt-to-Equity Ratio | 68.19 | 6.68 | Sun Pharmaceutical Industries Ltd. |
| PEG Ratio | 2.33 | 3.59 | Eris Lifesciences Ltd. |
| EV/EBITDA | 17.91 | 23.61 | Eris Lifesciences Ltd. |
| Profit Margin (TTM) | 14.06% | 19.21% | Sun Pharmaceutical Industries Ltd. |
| Operating Margin (TTM) | 26.38% | 26.17% | Eris Lifesciences Ltd. |
| EBITDA Margin (TTM) | 26.38% | 26.17% | Eris Lifesciences Ltd. |
| Return on Equity | 10.75% | 15.08% | Sun Pharmaceutical Industries Ltd. |
| Return on Assets (TTM) | 5.00% | 11.87% | Sun Pharmaceutical Industries Ltd. |
| Free Cash Flow (TTM) | $9.10B | $119.44B | Sun Pharmaceutical Industries Ltd. |
| Dividend Yield | 0.41% | 0.97% | Sun Pharmaceutical Industries Ltd. |
| 1-Year Return | -21.75% | 7.10% | Sun Pharmaceutical Industries Ltd. |
| Price-to-Sales Ratio (TTM) | 6.31 | 7.05 | Eris Lifesciences Ltd. |
| Enterprise Value | $217.40B | $3,783.37B | Sun Pharmaceutical Industries Ltd. |
| EV/Revenue Ratio | 7.09 | 6.66 | Sun Pharmaceutical Industries Ltd. |
| Gross Profit Margin (TTM) | 72.12% | 80.96% | Sun Pharmaceutical Industries Ltd. |
| Revenue per Share (TTM) | $225 | $237 | Sun Pharmaceutical Industries Ltd. |
| Earnings per Share (Diluted) | $31.54 | $45.46 | Sun Pharmaceutical Industries Ltd. |
| Beta (Stock Volatility) | -0.14 | 0.11 | Eris Lifesciences Ltd. |
Eris Lifesciences Ltd. vs Sun Pharmaceutical Industries Ltd. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Eris Lifesciences Ltd. | -1.44% | 1.41% | 0.98% | 5.69% | -12.73% | -7.79% |
| Sun Pharmaceutical Industries Ltd. | -0.09% | 0.96% | -3.84% | 1.28% | 0.50% | 4.93% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Eris Lifesciences Ltd. | -21.75% | 112.96% | 97.43% | 133.52% | 133.52% | 133.52% |
| Sun Pharmaceutical Industries Ltd. | 7.10% | 82.23% | 170.41% | 143.23% | 656.74% | 2,541.29% |
Performance & Financial Health Analysis: Eris Lifesciences Ltd. vs Sun Pharmaceutical Industries Ltd.
| Metric | ERIS | SUNPHARMA |
|---|---|---|
| Market Information | ||
| Market Cap | ₹193.36B | ₹3.88T |
| Market Cap Category | Mid cap | Large cap |
| 10 Day Avg. Volume | 174,049 | 3,903,142 |
| 90 Day Avg. Volume | 106,619 | 3,253,866 |
| Last Close | ₹1,384.40 | ₹1,806.00 |
| 52 Week Range | ₹1,200.00 - ₹1,900.00 | ₹1,548.00 - ₹1,916.60 |
| % from 52W High | -27.14% | -5.77% |
| All-Time High | ₹1,910.00 (Jun 09, 2025) | ₹1,960.35 (Sep 30, 2024) |
| % from All-Time High | -27.52% | -7.87% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.11% | 0.14% |
| Quarterly Earnings Growth | 0.19% | 0.16% |
| Financial Health | ||
| Profit Margin (TTM) | 0.14% | 0.19% |
| Operating Margin (TTM) | 0.26% | 0.26% |
| Return on Equity (TTM) | 0.11% | 0.15% |
| Debt to Equity (MRQ) | 68.19 | 6.68 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹226.84 | ₹324.46 |
| Cash per Share (MRQ) | ₹5.49 | ₹115.87 |
| Operating Cash Flow (TTM) | ₹7.57B | ₹110.84B |
| Levered Free Cash Flow (TTM) | ₹3.52B | ₹109.29B |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.41% | 0.97% |
| Last 12-Month Dividend | ₹7.35 | ₹16.50 |
Valuation & Enterprise Metrics Analysis: Eris Lifesciences Ltd. vs Sun Pharmaceutical Industries Ltd.
| Metric | ERIS (Apr 24, 2026) | SUNPHARMA (Apr 24, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 44.25 | 36.73 |
| Forward P/E | 27.76 | 29.48 |
| PEG Ratio | 2.33 | 3.59 |
| Price to Sales (TTM) | 6.31 | 7.05 |
| Price to Book (MRQ) | 6.15 | 5.15 |
| Market Capitalization | ||
| Market Capitalization | ₹193.36B | ₹3.88T |
| Enterprise Value | ₹217.40B | ₹3.78T |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 7.09 | 6.66 |
| Enterprise to EBITDA | 17.91 | 23.61 |
| Risk & Other Metrics | ||
| Beta | -0.14 | 0.11 |
| Book Value per Share (MRQ) | ₹226.84 | ₹324.46 |
Financial Statements Comparison: Eris Lifesciences Ltd. vs Sun Pharmaceutical Industries Ltd.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | ERIS (2025) | SUNPHARMA (2025) |
|---|---|---|
| Revenue/Sales | 28.79B | 520.41B |
| Cost of Goods Sold | 7.30B | 121.98B |
| COGS % of Revenue | 25.4% | 23.4% |
| Gross Profit | 21.49B | 398.44B |
| Gross Margin | 74.6% | 76.6% |
| Research & Development | 24.40M | N/A |
| Operating Income (EBIT) | 7.03B | 125.81B |
| Operating Margin | 24.4% | 24.2% |
| EBITDA | 10.33B | 167.25B |
| EBITDA Margin | 35.9% | 32.1% |
| Pre-Tax Income | 4.89B | 137.52B |
| Pre-Tax Income % of Revenue | 17.0% | 26.4% |
| Income Tax | 1.14B | 27.72B |
| Income Tax % of Revenue | 4.0% | 5.3% |
| Net Income (Profit) | 3.75B | 109.65B |
| Profit Margin | 13.0% | 21.1% |
Balance Sheet & Liquidity Metrics
| Metric | ERIS (2025) | SUNPHARMA (2025) |
|---|---|---|
| Cash & Equivalents | 2.00B | 102.69B |
| Total Current Assets | 12.23B | 526.24B |
| Total Current Assets % of Revenue | 42.5% | 101.1% |
| Total Current Liabilities | 13.81B | 181.94B |
| Total Current Liabilities % of Revenue | 48.0% | 35.0% |
| Long-Term Debt | 17.82B | 3.58B |
| Long-Term Debt % of Revenue | 61.9% | 0.7% |
| Total Shareholders Equity | 32.72B | 724.86B |
| Retained Earnings | 27.93B | 578.62B |
| Retained Earnings % of Revenue | 97.0% | 111.2% |
| Property, Plant & Equipment | 2.36B | 100.36B |
Cash Flow Statement Comparison
| Metric | ERIS (2025) | SUNPHARMA (2025) |
|---|---|---|
| Operating Cash Flow | 7.57B | 110.84B |
| Operating Cash Flow % of Revenue | 26.3% | 21.3% |
| Capital Expenditures | -1.55B | -20.68B |
| Free Cash Flow | 9.10B | 119.44B |
| FCF Margin | 31.6% | 23.0% |
| Debt Repayment | -18.34B | -43.44B |
| Common Stock Repurchase | N/A | -29.00B |
Short Interest & Institutional Ownership Analysis
| Metric | ERIS | SUNPHARMA |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Shares Outstanding | 138.54M | 2.40B |
| Float Shares | 43.42M | 1.07B |
| % Held by Insiders | 68.05% | 55.62% |
| % Held by Institutions | 21.83% | 28.69% |
| % Held by Public | 10.12% | 15.69% |
Dividend Analysis & Yield Comparison: Eris Lifesciences Ltd. vs Sun Pharmaceutical Industries Ltd.
| Metric | ERIS | SUNPHARMA |
|---|---|---|
| Last 12-Month Dividend | ₹7.35 | ₹16.50 |
| Last 12-Month Dividend Yield | 0.41% | 0.97% |
| 3-Year Avg Annual Dividend | ₹4.90 | ₹17.33 |
| 3-Year Avg Dividend Yield | 0.82% | 0.51% |
| 3-Year Total Dividends | ₹14.70 | ₹52.00 |
| Ex-Dividend Date | Feb 13, 2025 | Feb 05, 2026 |